Protocol: ADX-324-101. A phase I, single ascending dose study in healthy volunteers and an expansion cohort in patients with hereditary angioedemia to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ADX-324 (Interim Analysis#1)
Report published in 2023 by
Tahlia Meola,
Stephanie Reuter Lange 
